The company also reported completion of long-term follow-up on 20 patients treated with the cPAX Aneurysm treatment system in a clinical study which was completed in May.
Eric Timko, president and CEO of NeuroVasx, said: “We are very pleased with the results we achieved in our clinical study. The long term follow-up data further supports the clinical effectiveness of cPAX. The company is eager to share the results of our study with the physician community.”